Vicinitas Therapeutics Launches With $65 Million in Series A Financing to Advance Precision Medicines to Stabilize Key Proteins to Treat Disease
Retrieved on:
Thursday, July 28, 2022
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Novartis, Lists of diseases, DUB, Gene, Novartis Institute for Tropical Diseases, Doctor of Philosophy, Nutritional science, CFTR, Protein, Cell death, Research, General partnership, Chimera, Cancer, Technology, Deubiquitinating enzyme, Proximity, Berkeley, Associate professor, Industry, Biomedical Research, Health, Howard Hughes Medical Institute, Princeton University Department of Chemistry, UC, Nature Chemical Biology, Science, Therapy, OTUB1, Chemical biology, University, GV, University of California, Berkeley, Cell biology, Drug discovery, Associate, UCSF, WEE1, Patient, Department, Cystic fibrosis, Toxicology, Pharmaceutical industry, Vaccine, Fine chemical, Management, Microscope, Chemistry, Series
Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, today launched with $65 million in Series A financing.
Key Points:
- Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, today launched with $65 million in Series A financing.
- Many diseases, including cancer and monogenic diseases, are often caused by specific proteins that are abnormally degraded and lost from the cell.
- In cancer, protective tumor suppressors are aberrantly destroyed, allowing cancer cells to circumvent cell death, thus promoting unobstructed cell proliferation.
- Vicinitas Therapeutics is a biotechnology company focused on targeted protein stabilizers known as Deubiquituinase Targeting Chimeras (DUBTACs).